Yuxi Wang1, Yong Zhang2, Junbo Chen3, Minjin Wang4, Ting Zhang2, Wenxin Luo1, Yalun Li1, Yangping Wu1, Bo Zeng1, Kaixiang Zhang5, Ruijie Deng2, Weimin Li1. 1. Department of Respiratory and Critical Care Medicine, West China Medical School/West China Hospital, Sichuan University, Chengdu 610041, China. 2. College of Biomass Science and Engineering, Healthy Food Evaluation Research Center, Sichuan University, Chengdu 610065, China. 3. Analytical & Testing Center, Sichuan University, Chengdu, Sichuan 610064, China. 4. Department of Laboratory Medicine, West China Hospital of Sichuan University, Chengdu 610041, China. 5. School of Pharmaceutical Sciences, Key Laboratory of Targeting Therapy and Diagnosis for Critical Diseases, Zhengzhou University, Zhengzhou 450001, China.
Abstract
The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused a global health emergency, and its gene mutation and evolution further posed uncertainty of epidemic risk. Herein, we reported a light-up CRISPR-Cas13 transcription amplification method, which enables the detection of SARS-CoV-2 and its mutated variants. Sequence specificity was ensured by both the ligation process and Cas13a/crRNA recognition, allowing us to identify viral RNA mutation. Light-up RNA aptamer allows sensitive output of amplification signals via target-activated ribonuclease activity of CRISPR-Cas13a. The RNA virus assay has been designed to detect coronavirus, SARS-CoV-2, Middle East respiratory syndrome (MERS), and SARS, as well as the influenza viruses such as, H1N1, H7N9, and H9N2. It was accommodated to sense as low as 82 copies of SARS-CoV-2. Particularly, it allowed us to strictly discriminate key mutation of the SARS-CoV-2 variant, D614G, which may induce higher epidemic and pathogenetic risk. The proposed RNA virus assays are promising for point-of-care monitoring of SARS-CoV-2 and its risking variants.
The outbreak of severe acute respiratory syndrome coronavirus 2 (n class="Species">SARS-CoV-2) caused a global health emergency, and its gene mutation and evolution further posed uncertainty of epidemic risk. Herein, we reported a light-up CRISPR-Cas13 transcription amplification method, which enables the detection of SARS-CoV-2 and its mutated variants. Sequence specificity was ensured by both the ligation process and Cas13a/crRNA recognition, allowing us to identify viral RNA mutation. Light-up RNA aptamer allows sensitive output of amplification signals via target-activated ribonuclease activity of CRISPR-Cas13a. The RNA virus assay has been designed to detect coronavirus, SARS-CoV-2, Middle East respiratory syndrome (MERS), and SARS, as well as the influenza viruses such as, H1N1, H7N9, and H9N2. It was accommodated to sense as low as 82 copies of SARS-CoV-2. Particularly, it allowed us to strictly discriminate key mutation of the SARS-CoV-2 variant, D614G, which may induce higher epidemic and pathogenetic risk. The proposed RNA virus assays are promising for point-of-care monitoring of SARS-CoV-2 and its risking variants.
The worldwide outbreak of severe acute respiratory syndrome coronavirus 2 (n class="Species">SARS-CoV-2) has
led us to a global health emergency. Until Oct 5th, 2020, coronavirus disease in 2019
(Covid-19) was reported to have infected 35.1 million people and caused more than 1 million
deaths. Uniquely, RNA viruses exhibit high gene evolution rates because of the frequent
error-prone replication.[1] The missense mutation, D614G, in the spike
protein of SARS-CoV-2 has been reported to endow the SARS-CoV-2 virus with 10-fold higher
infectivity, and it is now emerging as a predominant clade in some regions such as
Europe.[2] Nevertheless, tools to rapidly resolve mutations in SARS-CoV-2
variants are still lacking. Timely diagnostic tests for RNA viruses and their key mutations
will provide key data streams to inform strategies to mitigate pandemic outbreaks.
Nucleic acid (NA)-based tests directly target signature regions of RNA viruses and could,
in principle, provide high accuracy and sensitivity for molecular
diagnosis.[3−5] Thus, NA-based detection
has become the gold standard for diagnosing RNA virus associated diseases, such as Covid-19
aene">nd n class="Species">Ebola.[6,7] In the
Covid-19 pandemic outbreak, NA tests are intensively proceeded and play key roles in patient
diagnosis and pandemic control.[4,6] In a typical NA test, target viral RNAs are transferred to cDNA via the
reverse-transcription process, followed by either PCR or isothermal amplification to obtain
abundant copies of target sequences.[8,9] PCR coupling with real-time fluorescence monitoring allows accurate and
sensitive quantification of RNA viruses. Complementarily, isothermal amplification
techniques such as recombinase polymerase amplification[10] and
loop-mediated isothermal amplification (LAMP)[11,12] allow us to use precise temperature-control PCR
instruments, facilitating NA tests in field laboratories and other resource-limited
settings. Particularly, the introduction of CRISPR-based approaches using either
Cas13a[13] or Cas12a[14] to detect amplified products
further improves the sensitivity and sequence specificity of NA tests.[15−18] Albeit NA tests being a
great success, the currently available NA-based test techniques have not been fully explored
to profile the mutation of SARS-CoV-2, which can provide key information on infectivity and
virulence. In addition, to specifically identify amplification products and record the
amplification process, RNA/DNA probes are chemically modified with multiple tags such as
fluorophores and quenchers. On-demand modification of NAs may reduce the robustness of NA
tests and sharply increase the test cost. In addition, the involvement of reverse
transcription still remains unoptimizable for RNA detection because of the relatively high
error rate.[19−21]
Herein, we report a method for profiling of SARS-CoV-2 aene">nd its mutated variaene">nts via a
light-up RNA aptamer signaling-CRISPR-Cas13 amplificatioene">n method. Light-up RNA aptan class="Disease">mers are
special NA affinities that could specifically bind with dyes and fix their structure to form
a light-up aptamer–dye complex.[22−24] The unlabeled
light-up RNA aptamer allows sensitive output of amplification signals via target-activated
ribonuclease activity of CRISPR-Cas13a. Alternative to reverse transcription, a ligation
strategy is introduced to initiate transcription amplification. Sequence specificity is
ensured by both the ligation process and Cas13a/crRNA recognition. The feasibility for
diagnosing RNA viruses was demonstrated using pseudovirus of SARS coronavirus, the Middle
East respiratory syndrome (MERS) coronavirus, SARS-CoV-2, and influenza viruses. We applied
the RNA assays to profile the key mutation, D614G of SARS-CoV-2 variants, and detect
SARS-CoV-2 infection in throat swab, serum samples, and SARS-CoV-2 contaminations in food
packaging and seafood.
Experimental Section
Materials
All DNA sequences were synthesized by Shanghai Sangon Biological Engineering Technology
& Services Co., Ltd. (Shanghai, China) and purified by high performance liquid
chromatography. The 5′ end of the presubstrate B was phosphorylated. Phi29 DNA
polymerase (cat. no. EP0094), T7 RNA polymerase (cat. no. EP0111), NTP mixtures (cat. no.
R0481), n class="Chemical">Lipofectamine 3000 (cat. no. L3000001), Random Hexamer primers (cat. no. SO142),
RiboLock RNase Inhibitors (cat. no. EO0832), RevertAid RT (cat. no. K1691), and SYBR Green
qPCR Supermix (cat. no. 2171875) were purchased from Thermo Fisher Scientific (Waltham,
USA). T4 RNA ligase 2 (cat. no. M0239S) and dNTP mixtures (cat. no. N0447S) were provided
by New England Biolabs (Beijing, China). MolPure Viral DNA/RNA Kit (cat. no. 19321ES50)
was bought from Yeasen Biotech Co., Ltd. (Shanghai, China). Cas13a protein (cat. no.
32117) was bought from Tolo Biotech Co., Ltd. (Shanghai, China). DFHBI-1T dyes (cat. no.
410-1 mg) were purchased from Lucerna Technologies (NY, USA). Gelred dyes (cat. no. 41001)
were bought from Biotium (Beijing, China). Total RNA extracted from influenza viruses,
H1N1, H7N9, and H9N2 was kindly supplied by Prof. Yi Shi and group (CAS Key Laboratory of
Pathogenic Microbiology and Immunology, Chinese Academy of Sciences, Beijing, China).
Preparation of Pseudovirus
To generate MERS, SARS, aene">nd n class="Species">SARS-CoV-2 pseudovirus, we applied the lentiviral vector
system to produce the pseudoviruses with key genes including the N gene, E gene, and S
gene (Figures S1 and S2, in the Supporting Information). The key genes including N gene, E gene, and S gene
were synthesized and cloned into the PacI and NheI sites of the pCMV3 vector. The
constructed recombinant plasmids were confirmed by DNA sequencing. 5 × 106
HEK293T cells were cotransfected with 6 μg of recombinant plasmids using the
Lipofectamine 3000 transfection reagent. Cells were then transferred to fresh DMEM and
kept for 12 h. The supernatants containing the pseudoviruses were harvested 48–72 h
after transfection and filtered through a 0.45 μm filter.
Preparation of crRNA and Light-Up RNA Aptamer, Broccoli
The light-up RNA aptamer, broccoli, was chosen because of its high structure stability
and fluorescence turn-on ratio.[25−27] The crRNA
sequences were designed according to the reported CRISPR-Cas13a assays.[14] The mixtures containing 4 μL of DNA templates (Table S1, in the Supporting Information) of crRNA or broccoli, 4 μL of promoter
sequences, 4 μL of phi29 DNA polymerase buffer, and 10.1 μL of H2O
were aene">nnealed at 90 °C for 5 min aene">nd at room temperature for 30 min. Then, 0.4
μL of phi29 DNA polymerase (10 U/μL) aene">nd 1 μL of n class="Chemical">dNTP mixtures (10 mM
each for dATP, dGTP, dCTP, and dTTP) were added to the mixtures, and they were incubated
at 30 °C for 30 min. After the inactivation procedure, the above mixtures were mixed
with 0.5 μL of T7 RNA polymerase (20 U/μL), 8 μL of T7 RNA polymerase
buffer, and 2 μL of NTP mixtures (10 mM each for ATP, GTP, CTP, and TTP) at 37
°C overnight to obtain the transcription product of crRNA and broccoli. The
concentration of obtained crRNA and broccoli was quantified using a microplate reader
Synergy H1 (BioTek, USA).
RNA Virus Detection
RNA genes were either extracted from pseudovirus using the MolPure Viral DNA/RNA Kit
according to the maene">nufacturer’s instructions or obtained by
in-vitro traene">nscription. 4 μL of RNA samples, 4 μL of
presubstrate A (10 μM), 4 μL of presubstrate B (10 μM), 4 μL of
promoter sequences (10 μM), 1 μL of T4 RNA ligase 2 (10 U/μL), 2
μL of 10×T4 RNA ligase 2 buffer, aene">nd 8.5 μL of n class="Chemical">H2O were mixed
and incubated at 37 °C for 30 min to proceed the ligation procedure. Transcription
amplification was carried out by adding 0.5 μL of T7 RNA polymerase (20 U/μL),
8 μL of T7 RNA polymerase buffer, and 2 μL of NTP mixtures (10 mM each for
ATP, GTP, CTP, and TTP) at 37 °C. A volume of 40 μL was used to detect RNA
viruses containing 4 μL of transcription products, 4 μL of broccoli (10
μM), 4 μL of crRNA (10 μM), 0.2 μL of LwaCas13a (10 μM), 4
μL of 10× Cas13a buffer (supplied by Tolo Biotech), 4 μL of DFHB-1T
solution (100 nM), and 19.8 μL of H2O. The mixture remained at 37 °C
for 20 min for the cleavage of light-up RNA aptamer, broccoli. Next, the abovementioned
mixture was prepared for fluorescence analysis.
Fluorescence Spectra and Gel Electrophoresis Analysis
Fluorescent spectra were analyzed by a microplate reader Synergy H1 (BioTek, USA). The
excitation/emission wavelengths were 468/498 nm. The real-time fluorescence analysis
procedure was carried out by Synergy H1, with excitation/emission wavelengths of 468/498
nm and a measurement time interval of 30 s. Nondenaturing gel electrophoresis analysis was
carried out at a final reaction volume of 6 μL, containing 5 μL of
oligonucleotides aene">nd 1 μL of gel loading buffer. n class="Chemical">Agarose was prepared with 50×
TAE buffer and 20× Gelred dyes. Then, the gel electrophoresis was carried out at 150
V for 40 min and imaged using a Gel Doc XR+ system (Bio-Rad, USA).
Detection of SARS-CoV-2 in Throat Swab, Food Package, and Frozen Belt Fish
Samples
All COVID-19 coronavirus RNA clinical samples were collected aene">nd aene">nalyzed from The West
China Hospital of Sichuaene">n University (Ethical Approval no. 2020(100)). Viral RNAs in
throat swab samples were obtained by RNA extraction aene">nd virus RNA detection procedures,
the same as that done in the buffer conditions. For nonclinical throat swab samples, 100,
500, aene">nd 2000 copies of n class="Species">SARS-CoV-2 pseudovirus were spiked in the liquid samples. For food
package samples, 200 μL of solutions containing 0, 500, or 2000 copies of SARS-CoV-2
pseudovirus were spayed in a surface area of the package (with an area with a diameter of
∼3 cm) to mimic the contamination of SARS-CoV-2 virus. 300 μL of washing
buffer was used to collect the SARS-CoV-2 virus on the surface of the food package. For
frozen belt fish samples, fish tissues were cut and grinded by SCIENTZ-48 tissuelyser
(Ningbo Scientz Biotechnology Co., Ltd, China), and then different amounts of SARS-CoV-2
pseudovirus were spiked in the samples. Total RNA was obtained from the SARS-CoV-2
virus-contaminated food package and belt fish samples using the MolPure Viral DNA/RNA Kit
and analyzed by the proposed RNA assay (Figure S3, in the Supporting Information).
RT-qPCR Analysis
A 20 μL reverse transcription assay was set up containing 1 μL of Random
Hexamer primer, 2 μL of RNA, 2 μL of dNTP (10 mM), 4 μL of 5×
reactioene">n buffer, 1 μL of RiboLock RNase Iene">nhibitor (20 U/μL), 1 μL of
RevertAid RT (200 U/μL), aene">nd 9 μL of n class="Chemical">H2O. The mixture was incubated
for 5 min at 25 °C followed by 60 min at 42 °C, and the reaction was terminated
by heating at 70 °C for 5 min. The products were used in qPCR. A 20 μL reaction
was set up containing 2 μL of products obtained in the previous step, 10 μL of
SYBR Green qPCR Supermix, 2.5 μL of F-primer (4 μM), and 2.5 μL of
R-primer (4 μM), followed by 95 °C for 10 min, and then 40 cycles were carried
out at 95 °C for 15 s and 60 °C for 30 s in a Bio-rad CFX96 Touch RT-PCR system
(Bio-Rad, USA).
Results and Discussion
Working Principles
Two processes were designed to amplify and sense the presence of RNA viruses (Figure ). First, a split couple of probes,
presubstrate A and presubstrate B, were designed to target the specific RNA sequence of
SARS-CoV-2. A promoter sequence was aene">nchored in presubstrate B. A specific ligation
performed by T4 RNA ligase 2 allowed strict identification of viral RNA sequences,
yielding a template for in vitro traene">nscription. The ligation-based
recognition process evaded reverse traene">nscription, thus evolving a reverse
traene">nscription-free aene">nd isothermal amplification process for RNA virus detection. Next,
aene">nother sequence-specific recognition process was achieved through a CRISPR RNA (crRNA)
that recruited a Cas13a protein aene">nd activated its ribonuclease activity for RNA
substrates. Remarkably, the introduction of light-up RNA aptamer empowered CRISPR-Cas13a
for label-free detection of target RNA sequences. Dual recognition aene">nd dual amplification
steps via the integration of ligation-initiated traene">nscription amplification aene">nd
CRISPR-Cas13a amplification allowed us to ensure high specificity to resolve
single-nucleotide variations aene">nd high sensitivity to detect low abundaene">nt RNA viruses.
Figure 1
Schematics of the principle of detection of SARS-CoV-2 and its mutated variants via a
light-up RNA aptamer signaling-CRISPR-Cas13 amplification method. Single-stranded RNA
from SARS-CoV-2 serves as a template for the ligation of presubstrate probes
(presubstrate A and presubstrate B), yielding a template for transcription
amplification. Unlabeled light-up RNA aptamer allows sensitive output of amplification
signals via the target-activated ribonuclease activity of CRISPR-Cas13a. The
specificity of RNA sequences can be ensured by the ligation process and CRISPR-Cas13a
recognition, thus allowing profiling of RNA viruses with a single-nucleotide
resolution.
Schematics of the principle of detection of SARS-CoV-2 aene">nd its mutated variaene">nts via a
light-up RNA aptamer signaling-CRISPR-Cas13 amplificatioene">n method. Single-straene">nded RNA
from n class="Species">SARS-CoV-2 serves as a template for the ligation of presubstrate probes
(presubstrate A and presubstrate B), yielding a template for transcription
amplification. Unlabeled light-up RNA aptamer allows sensitive output of amplification
signals via the target-activated ribonuclease activity of CRISPR-Cas13a. The
specificity of RNA sequences can be ensured by the ligation process and CRISPR-Cas13a
recognition, thus allowing profiling of RNA viruses with a single-nucleotide
resolution.
The working principle was investigated via fluorescence and electrophoresis analysis. We
designed presubstrate probes targeting the N genes of SARS-CoV-2. The targeting site
regioene">ns were choseene">n according to the published work.[12] The light-up
effect of the broccoli RNA aptamer-n class="Chemical">DFHBI-1T complex was confirmed first. With the addition
of RNA aptamer, broccoli, the fluorescence of DFHBI-1T was enhanced by 430 times (Figure A). The efficient turn-on of the RNA aptamer
broccoli-DFHBI-1T complex promised a high signal-to-background ratio of RNA
aptamer-signaling detection. The addition of Cas13a/crRNA induced no significant
fluorescence variation. The presence of substrate sequences, however, led to a dramatic
reduction of fluorescence (from 23,590 to 4183) (Figure A). The result indicated that substrate sequences activated the ribonuclease
activity of Cas13a and substantially digested the RNA aptamer, broccoli. The substrate
sequence-activated Cas13a gave an amplification effect for leveraging the response of the
RNA aptamer signaling-CRISPR-Cas13 system.
Figure 2
Investigation of the working principle of the light-up RNA aptamer
signaling-CRISPR-Cas13 amplification strategy. (A) Fluorescence analysis of
CRISPR-Cas13 induced cleavage of light-up RNA aptamer; (B) fluorescence analysis of
RNA aptamer signaling-CRISPR-Cas13 response toward viral RNA. 5000 copies of RNA virus
were added, and the concentrations of presubstrate A, presubstrate B, Cas13a, and
DFHB-1T were 1 μM, 1 μM, 0.05 μM, and 10 nM, respectively, and the
excitation wavelength was 468 nm. (C) Electrophoresis analysis of viral RNA-initiated
transcription amplification.
Investigation of the working principle of the light-up RNA aptamer
signaling-CRISPR-Cas13 amplification strategy. (A) Fluorescence analysis of
CRISPR-Cas13 induced cleavage of light-up RNA aptamer; (B) fluorescence analysis of
RNA aptamer signaling-CRISPR-Cas13 response toward viral RNA. 5000 copies of RNA virus
were added, and the concentrations of presubstrate A, presubstrate B, Cas13a, and
DFHB-1T were 1 μM, 1 μM, 0.05 μM, and 10 nM, respectively, and the
excitation wavelength was 468 nm. (C) Electrophoresis analysis of viral RNA-initiated
transcription amplification.We further investigated the ligation-triggered transcription amplification process. The
presence of N genes dramatically reduced the fluorescence of the RNA aptamer
broccoli-DFHBI-1T complex (Figure B), while the
elimination of T7 RNA polymerase led to no significaene">nt fluorescence variation. Thus, the
substaene">ntial cleavage of broccoli, RNA aptamer, resulted from the N gene-initiated
traene">nscription amplification. The process was further demonstrated by electrophoresis
aene">nalysis. There emerged a lag-behind baene">nd (line 3, Figure C), which corresponded to aene">n NA complex with higher molecule weight
compared with the presubstrate probes. It indicated the binding of N gene sequences with
both two presubstrate probes. Further addition of T7 RNA polymerase promoted the
production of tremendous substrate sequences (line 1, Figure C). Iene">n contrast, the deletion of N gene sequences only produced the
fragment of substrate sequences corresponding to presubstrate B (line 2, Figure C).
Profile Signatures of Coronavirus and Influenza Viruses
We then explored the ability of the RNA aptamer signaling-CRISPR-Cas13 amplification
strategy for profiling coronavirus aene">nd n class="Species">influenza viruses. Coronaviruses are highly
epidemic and pathogenic, thus posing a great threat to human health.[3]
We chose three coronavirus species, MERS, SARS, and SARS-CoV-2, to estimate the
feasibility of the proposed assays for RNA virus analysis. To eliminate the infection risk
of these viruses, their pseudovirus counterparts were used instead. N genes, E genes, and
ORF1 a/b genes of MERS, SARS, and SARS-CoV-2 were packaged in lentiviruses. The symptoms
of infecting influenza virus are very similar to that of SARS-CoV-2.[4]
Simultaneous profiling of the influenza virus can improve the fidelity of the SARS-CoV-2
diagnosis. Thus, probes for detecting influenza viruses (targeting neuraminidase genes)
including H1N1, H7N9, and H9N2 were further designed.
First, we proposed strategies for detecting SARS-CoV-2. Curreene">nt US FDA EUA guidaene">nce use
both N geene">nes aene">nd E geene">nes to coene">nfirm the diagnosis of n class="Species">SARS-CoV-2.[12]
Besides, the human RNase P gene is often chosen as a control to ensure the success of
sampling. Thus, a probe set of presubstrate probes was designed targeting N genes, E genes
of SARS-CoV-2, and RNase P gene. In vitro-transcribed N genes, E genes,
and RNase P genes were used. The sequences of target RNA and Presubstrate probes are
presented in Figure . The RNA aptamer
signaling-CRISPR-Cas13 amplification strategy can specifically sense N genes, E genes of
SARS-CoV-2, and RNase P gene (Figure A). Only
the presence of the RNase P gene led to a slight reduction of fluorescence using probes
targeting N genes. A parallel test of these three genes can imply the detection of the
infection of SARS-CoV-2 with high fidelity. We then set to use the RNA aptamer
signaling-CRISPR-Cas13 amplification strategy to profile different coronaviruses. N genes
and E genes of three coronaviruses, MERS, SARS, and SARS-CoV-2 were chosen as target
sites. We demonstrated that the RNA assay can distinguish these 3 coronavirus species, and
no obvious cross-reactivity for related coronaviruses strains using probes targeting N
genes and E genes (Figures B and S4 in the
Supporting Information). The result implied the high specificity for
profiling coronaviruses. In addition, RNA aptamer signaling-CRISPR-Cas13 amplification was
applied for screening the influenza virus (Figure C). The minor cross-reactivity among influenza virusesH1N1, H7N9, and H9N2
further revealed the universality of the strategy for profiling signatures of RNA viruses.
Thus, RNA aptamer signaling-CRISPR-Cas13 amplification allows the detection of different
RNA viruses. Benefiting from the isothermal features of transcription amplification and
homogenous reaction conditions, RNA aptamer signaling-CRISPR-Cas13 amplification promises
high-throughput screening of RNA viruses using fluorescent microplate readers.
Figure 3
Profile of coronaviruses and influenza viruses. (A) Probes were designed to target N
genes and E genes of SARS-CoV-2, as well as human RNase P genes; (B) detection of
coronavirus species including MERS, SARS, and SARS-CoV-2; (C) detection of influenza
viruses including H1N1, H7N9, and H9N2. The genome map shows the target sequences of
different viruses and the sequences of Presubstrate probes.
F0 and F indicate the fluorescence
intensity in the absence and presence of RNA viruses or genes, respectively. 5000
copies of RNA viruses were added, and the concentrations of presubstrate A,
presubstrate B, Cas13a, and DFHB-1T were 1 μM, 1 μM, 0.05 μM, and 10
nM, respectively, and the excitation wavelength was 468 nm.
Profile of coronaviruses aene">nd n class="Species">influenza viruses. (A) Probes were designed to target N
genes and E genes of SARS-CoV-2, as well as human RNase P genes; (B) detection of
coronavirus species including MERS, SARS, and SARS-CoV-2; (C) detection of influenza
viruses including H1N1, H7N9, and H9N2. The genome map shows the target sequences of
different viruses and the sequences of Presubstrate probes.
F0 and F indicate the fluorescence
intensity in the absence and presence of RNA viruses or genes, respectively. 5000
copies of RNA viruses were added, and the concentrations of presubstrate A,
presubstrate B, Cas13a, and DFHB-1T were 1 μM, 1 μM, 0.05 μM, and 10
nM, respectively, and the excitation wavelength was 468 nm.
Identify Gene Mutations of SARS-CoV-2
The ability to profile the mutation of RNA viruses allows precise estimation of the
epidemic and pathogenetic risk. An amino acid change in the virus’ spike protein,
n class="Mutation">D614G, emerged early during the pandemic, and viruses containing G614 are now dominant in
many places around the world.[2] Although plenty of NA assays have been
developed to diagnosis COVID19, rare tools are available to resolve gene mutations of
SARS-CoV-2 virus. To estimate the ability of the assay to profile D614G mutation of
SARS-CoV-2, lentiviruses containing partial S genes (wild or with D614G mutation), N
genes, E genes, and ORF1 a/b genes of SARS-CoV-2 were constructed (Figure S1 in the
Supporting Information). We designed a series of Presubstrate probes
(1–6) to target the D614G mutation. Wild and mutated SARS-CoV-2 pseudoviruses were
sequenced, and the presence of the D614G mutation was confirmed (Figure
A). D614G mutation anchored in either presubstrate A probe or
presubstrate B probe would be dramatically discriminated by the RNA assay (Figures B and S5, in the Supporting Information). We further defined a discrimination rate as the
ratio of fluorescence response of Presubstrate probes toward its corresponding target RNA
sequences (wild or mutated) to nontarget ones. We found that the position of mutation
anchored close to the ligation site of presubstrate probes would yield an improved
discrimination rate (such as Presubstrate probe 2 and 3). We moved the crRNA binding sites
by designing crRNA with different recognition sequences. We found that the highest
specificity was achieved when the mutated site was on the 5′-terminal of
recognition sequences of crRNA (Figure S6, in the Supporting Information).
Figure 4
Identify D614G mutations of SARS-CoV-2 variants. (A) Illustration of the position of
D614G mutations using a series of presubstrate probes (1-6), sequencing result of
mutated and wild SARS-CoV-2, and design of presubstrate probes (1-6) for identifying
D614G mutations; (B) fluorescence response (F0 –
F) toward mutated and wild SARS-CoV-2 using presubstrate probes
1–6. F0 and F indicate the
fluorescence intensity in the absence and presence of RNA virus, respectively; (C)
discrimination rates for detecting D614G mutations using presubstrate probes
1–6; (D) fluorescence response toward wild and mutated SARS-CoV-2 virus using
presubstrate probes 3. 5000 copies of RNA virus were added, and the concentrations of
presubstrate A, presubstrate B, Cas13a, DFHB-1T, and SYBR Green II were 1 μM, 1
μM, 0.05 μM, 10 nM, and 1×, respectively. The excitation and emission
wavelengths were 468 and 498 nm, respectively.
Identify D614G mutatioene">ns of n class="Species">SARS-CoV-2 variants. (A) Illustration of the position of
D614G mutations using a series of presubstrate probes (1-6), sequencing result of
mutated and wild SARS-CoV-2, and design of presubstrate probes (1-6) for identifying
D614G mutations; (B) fluorescence response (F0 –
F) toward mutated and wild SARS-CoV-2 using presubstrate probes
1–6. F0 and F indicate the
fluorescence intensity in the absence and presence of RNA virus, respectively; (C)
discrimination rates for detecting D614G mutations using presubstrate probes
1–6; (D) fluorescence response toward wild and mutated SARS-CoV-2 virus using
presubstrate probes 3. 5000 copies of RNA virus were added, and the concentrations of
presubstrate A, presubstrate B, Cas13a, DFHB-1T, and SYBR Green II were 1 μM, 1
μM, 0.05 μM, 10 nM, and 1×, respectively. The excitation and emission
wavelengths were 468 and 498 nm, respectively.
We further proceed to estimate the dual recognition effect on the specificity of D614G
discriminatioene">n. The assays were carried out with aene">nd without Cas13a-crRNA recognitioene">n aene">nd
cleavage amplificatioene">n. For assays without Cas13a-crRNA recognitioene">n aene">nd cleavage
amplificatioene">n, the products of traene">nscriptioene">n amplificatioene">n were moene">nitored using Sybr Greeene">n
II (a dye that turns oene">n its fluoresceene">nce by binding with single-straene">nded RNA). The
involvemeene">nt of Cas13a-gRNA recognitioene">n would significaene">ntly improve the ability to
discriminate the n class="Mutation">D614G mutation, especially, the D614G mutation which was located on the
crRNA binding sites (Figures C and S7, in the
Supporting Information). The result further implied that the dual
recognition mechanism based on the ligation process and Cas13a recognition can increase
the specificity to discriminate single-nucleotide variation.
We estimated the ability of the assay to discriminate D614G mutatioene">ns in the preseene">nce of
wild viral RNAs. The fluoresceene">nt respoene">nse of the assay toward 1, 5, 10, aene">nd 50 amounts of
wild viral RNAs compared to n class="Mutation">D614G mutated viral RNAs was tested (Figure
D). The increasing concentration of wild viral RNAs only
slightly reduced the fluorescence of the assays. Even the amount of wild viral RNAs was 50
times that of D614G mutated viral RNAs, and the fluorescent variation was much smaller
than that in the presence of D614G mutated viral RNAs. The results indicated that the
assay can identify mutated viral RNAs even in a much higher concentration of wild viral
RNAs. Thus, the presence of a dual recognition effect resulted from the ligation process
and Cas13a/crRNA recognition ensured a sufficient specificity to discriminate
single-nucleotide variation.
Quantification Performance
We optimized the molar ratio of Cas13a to crRNA (Figure S8, in the Supporting Information) and found that the cleavage of broccoli, RNA
aptamer, can be finished within 20 min (Figure S9 in the Supporting Information). Under the optimized condition, we estimated the
quantification performance of RNA aptamer signaling-CRISPR-Cas13 amplification for
detecting SARS-CoV-2. Dilutioene">ns of n class="Species">SARS-CoV-2 pseudovirus from 0 to 3000 copies were used
to determine the sensitivity of the RNA virus assay. As shown in Figure
B, the limit of detection (LoD) for our assay was estimated
to be 82 copies per reaction for the SARS-CoV-2 pseudovirus. Although, the sensitivity of
the RNA virus assay was slightly lower than that of RT-qPCR.[4,6,8] The proposal of
the RNA aptamer signaling-CRISPR-Cas13 amplification strategy eliminates the
reverse-transcription process and chemical labeling of NA probes; further, the isothermal
reaction condition further evades the dependence of expensive PCR instruments.
Particularly, the RNA virus assay allows us to resolve single-nucleotide variation of
SARS-CoV-2 (Table S2 in the Supporting Information). All these features promise its application for
diagnosing RNA virus and viral mutations in resource-limited settings.
Figure 5
Quantification of SARS-CoV-2. (A) Typical fluorescence spectra of RNA aptamer
signaling-CRISPR-Cas13 amplification strategy upon the addition of different copies of
SARS-CoV-2 pseudovirus (0, 1, 10, 100, 200, 300, 500, 1000, 1500, and 3000 copies);
(B) relationship between the copies of the SARS-CoV-2 pseudovirus and fluorescence
response. (Inset) Linear relationship between the copies of the SARS-CoV-2 pseudovirus
and fluorescence response. The error bars indicate the standard deviation of three
parallel measurements for each concentration of SARS-CoV-2 virus. The concentrations
of presubstrate A, presubstrate B, Cas13a, and DFHB-1T were 1 μM, 1 μM,
0.05 μM, and 10 nM, respectively. The excitation and emission wavelengths were
468 and 498 nm, respectively.
Quantification of SARS-CoV-2. (A) Typical fluoresceene">nce spectra of RNA aptamer
signaling-CRISPR-Cas13 amplificatioene">n strategy upoene">n the additioene">n of differeene">nt copies of
n class="Species">SARS-CoV-2 pseudovirus (0, 1, 10, 100, 200, 300, 500, 1000, 1500, and 3000 copies);
(B) relationship between the copies of the SARS-CoV-2 pseudovirus and fluorescence
response. (Inset) Linear relationship between the copies of the SARS-CoV-2 pseudovirus
and fluorescence response. The error bars indicate the standard deviation of three
parallel measurements for each concentration of SARS-CoV-2 virus. The concentrations
of presubstrate A, presubstrate B, Cas13a, and DFHB-1T were 1 μM, 1 μM,
0.05 μM, and 10 nM, respectively. The excitation and emission wavelengths were
468 and 498 nm, respectively.
Detection of SARS-CoV-2 in Throat Swabs, Food Packages, and Seafoods
We utilized the RNA aptamer signaling-CRISPR-Cas13 amplification strategy for detecting
SARS-CoV-2 virus from throat swabs, seafoods, aene">nd food packages. Throat swab samples are
commoene">nly used to diagnose n class="Disease">COVID-19. SARS-CoV-2 residues in cold-chain food and food
packages are highly risky for disease transmission.[28] 100, 500, and
2000 copies of SARS-CoV-2 pseudoviruses were spiked in throat swab solution samples or
smeared in frozen belt fish and food packages to mimic food contaminations. For throat
swab samples, the presence of 100 copies of SARS-CoV-2 pseudovirus particles led to an
obvious fluorescence response compared to that of the background (Figure
A). For food package and belt fish samples, the RNA virus
detection method outputted a signal close to the background with the presence of 100
copies of SARS-CoV-2 pseudoviruses, while it induced an obvious positive response when
SARS-CoV-2 pseudovirus particles were up to 500 copies. The decreased sensitivity for
detecting SARS-CoV-2 in food packages and belt fish samples may be ascribed to the loss of
virus during sample collection. Finally, we tested the proposed assays for analyzing
clinical throat swab samples. The samples were tested by RT-qPCR and sequencing, and then
analyzed by the proposed assay (Figures C, S10,
and S11, in the Supporting Information). The proposed assay can identify throat swab samples
of SARS-CoV-2 infectedpersons from that of healthy ones (Figure B, in the Supporting Information). The result preliminarily demonstrated the
feasibility of the proposed assay for diagnosing COVID-19. A further test with a larger
amount of COVID-19 clinical samples is needed to support its applications.
Figure 6
Detection of SARS-CoV-2 in throat swab, food packaging, frozen belt fish samples, and
clinical throat swab samples. (A) SARS-CoV-2 pseudovirus particles in different copies
were spiked in throat swab solutions to mimic infected samples, and spayed on surface
of food packages and frozen belt fish tissues to mimic food contaminations; (B)
detection of SARS-CoV-2 in clinical throat swab samples via CRISPR-Cas13-based assay;
(C) detection of SARS-CoV-2 in clinical throat swab samples by RT-qPCR. The
concentrations of presubstrate A, presubstrate B, Cas13a, and DFHB-1T were 1 μM,
1 μM, 0.05 μM, and 10 nM, respectively, and the excitation wavelength was
468 nm. Tests were carried in three replicates (two-tailed Student’s
t-test; **P < 0.01, ***P <
0.001, ****P < 0.0001; bars represent ± s.d).
Detection of SARS-CoV-2 in throat swab, food packaging, frozeene">n belt fish samples, aene">nd
clinical throat swab samples. (A) n class="Species">SARS-CoV-2 pseudovirus particles in different copies
were spiked in throat swab solutions to mimic infected samples, and spayed on surface
of food packages and frozen belt fish tissues to mimic food contaminations; (B)
detection of SARS-CoV-2 in clinical throat swab samples via CRISPR-Cas13-based assay;
(C) detection of SARS-CoV-2 in clinical throat swab samples by RT-qPCR. The
concentrations of presubstrate A, presubstrate B, Cas13a, and DFHB-1T were 1 μM,
1 μM, 0.05 μM, and 10 nM, respectively, and the excitation wavelength was
468 nm. Tests were carried in three replicates (two-tailed Student’s
t-test; **P < 0.01, ***P <
0.001, ****P < 0.0001; bars represent ± s.d).
Conclusions
In this work, we have demonstrated a method for the profiling of SARS-CoV-2 aene">nd its mutated
variaene">nts based oene">n a CRISPR-Cas13 amplificatioene">n principle. The CRISPR-Cas13-based
amplificatioene">n strategy allowed us to target aene">nd detect a series of RNA viruses including
n class="Species">coronaviruses SARS-CoV-2, MERS, and SARS, as well as influenza viruses such as, H1N1, H7N9,
and H9N2. The dual recognition processes via the ligation process and Cas13a/crRNA binding
ensure a high specificity to discriminate even a single-nucleotide variation in SARS-CoV-2.
Thus, the CRISPR-Cas13-based amplification strategy was accommodated to profile the
clinically significant mutation, D614G, of SARS-CoV-2 variants. The introduction of light-up
RNA aptamers for signaling target-initiated Cas13a/crRNA ribonuclease eliminates the use of
chemically labeled RNA substrates. The feasibility for profiling SARS-CoV-2 in throat swabs,
seafoods, and food packages promises the use of the assays for monitoring clinical and food
associated SARS-CoV-2 transmission.